CASI Pharmaceuticals, Inc. (OTC: CASIF)

CASI Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China the United States and globally. The company concentrates on hematology oncology autoimmune and organ transplant rejection therapeutic areas as well as other unmet medical needs. It has built infrastructure in China including sales marketing medical affairs regulatory and clinical development through subsidiaries CASI China and CASI Wuxi. The majority of operations are located in China with 222 full-time employees including a commercial team of 141 hematology and oncology sales and marketing specialists based in China. CASI Pharmaceuticals pursues its strategy by acquiring developing and launching medicines in the greater China market leveraging its China-based regulatory clinical and commercial capabilities and global drug development expertise.

CASI Pharmaceuticals generates revenue primarily through the commercial sale of its approved products in China. Key products include EVOMELA for multiple myeloma conditioning and palliative treatment FOLOTYN for relapsed or refractory peripheral T-cell lymphoma and CNCT19 for relapsed and refractory B-cell acute lymphoblastic leukemia. The company also distributes YuTuo under an agreement with Guangzhou Gloria Biosciences for the treatment of classical Hodgkin lymphoma and cervical cancer. Revenue is derived from product sales facilitated by third-party distributors who manage logistics and sales to healthcare providers including hospitals and clinics. Additionally the company earns revenue from milestone payments and royalties under licensing agreements with partners such as Juventas for CNCT19 and BioInvent for BI-1206 though current commercial revenue stems mainly from marketed products.

CASI Pharmaceuticals operates in a highly competitive biopharmaceutical industry where success depends on scientific innovation regulatory navigation and commercial execution. For EVOMELA it faces competition from domestically produced injectable melphalan products such as those from Xi'An Libang Pharmaceuticals which launched a propylene glycol-based formulation in September 2022 and Sichuan Huiyu Pharmaceutical which launched a Captisol-based formulation in March 2025. FOLOTYN competes with other treatments in the relapsed/refractory peripheral T-cell lymphoma market including Chidamide Liposomal Mitoxantrone and Golidocitinib all of which are included in China's National Reimbursement Drug List. CNCT19 encounters challenges due to the high volume of CAR-T clinical trials in China creating intense competition for eligible patients and limiting commercial accessibility. The company's competitive advantages include its established China-based infrastructure deep regulatory expertise with agencies like the NMPA and a diversified pipeline encompassing late-stage clinical candidates proprietary innovations and select high-quality pharmaceuticals targeting significant unmet medical needs in hematology immunology and transplant rejection.

CASI Pharmaceuticals serves patients in China primarily through its partnerships with third-party distributors. The company relies on China Resources Pharmaceutical Commercial Group International Trading Co Ltd for the exclusive distribution of EVOMELA in China. For FOLOTYN it uses China National Medicines Corporation Ltd as its sole distributor under an agreement valid until December 5 2026. Additionally it has a distribution agreement with Guangzhou Gloria Biosciences Co Ltd for YuTuo covering a three-year term starting in January 2025. These distributors supply products to government hospitals which represent over 90% of China's pharmaceutical market as well as to healthcare providers treating hematology oncology immunology and transplant patients. The company's internal commercial team supports these efforts through direct engagement with therapeutic area experts physicians and hospital centers to drive product adoption and market penetration.